National Cell Respository for Alzheimer's Disease (NCRAD) (U24)

描述（由申请人提供）：国家阿尔茨海默病细胞库（NCRAD）在美国国家老龄研究所（NIA）识别阿尔茨海默病（AD）风险人群和开发改进的治疗方法以延缓或预防疾病发作的努力中起着关键作用。NCRAD是与NIA达成的合作协议，作为所有NIA资助的痴呆研究的主要样本共享来源。在NIA和细胞库咨询委员会的建议下，NCRAD的使命是消除阻碍研究进展的关键障碍，以了解痴呆症的病因。为了实现这一目标，NCRAD有两个主要功能：样本银行和样本分发。NCRAD作为中央储存库，使用统一的协议和广泛的质量措施，从正在进行的NIA资助的研究中收集样本。储存样本的种类已经扩大到包括DNA、细胞系、血浆、血清、脑组织和RNA。NCRAD与国家阿尔茨海默病协调中心（NACC）密切合作，NACC是NIA的另一个核心机构，作为所有阿尔茨海默病中心（adc）的数据协调中心。NCRAD和NACC共同作为阿尔茨海默病遗传学联盟（ADGC）的关键资源，协调来自29个adc的样本收集。NCRAD还将样本广泛分发给研究人员，供他们自己分析，也分发给中心中心，在那里进行APOE基因分型，全基因组范围的SNP阵列，以及现在的全基因组和全外显子组测序研究。我们建议扩大成功的工作，具体目标如下：1. 为所有nia资助的痴呆症研究提供最先进的中央生物标本库，包括DNA、细胞系、血浆、血清、RNA和脑组织安全银行的详细标准操作程序。2. 通过向所有合格的研究人员分发数据和生物标本，以促进和促进样本共享。

DESCRIPTION (provided by applicant): The National Cell Repository for Alzheimer's Disease (NCRAD) plays a key role in the National Institute on Aging's (NIA) efforts to identify those at risk for Alzheimer disease (AD) and develop improved treatments to delay or prevent disease onset NCRAD was established as a cooperative agreement with the NIA to serve as the primary source of sample sharing for all NIA-funded dementia studies. Under the advisement of NIA and the Cell Bank Advisory Committee, it is the mission of NCRAD to remove critical barriers hindering research progress to understand the etiology of dementia. To achieve this goal, NCRAD has two primary functions: sample banking and sample distribution. NCRAD serves as a central repository banking samples from ongoing NIA funded studies using uniform protocols with extensive quality measures. The type of samples being banked has expanded to include DNA, cell lines, plasma, serum, brain tissue and RNA. NCRAD works closely with the National Alzheimer Coordinating Center (NACC), another NIA core facility that serves as the data coordinating center for all the Alzheimer Disease Centers (ADCs). Together, NCRAD and NACC serve as key resources within the Alzheimer Disease Genetics Consortium (ADGC), coordinating the collection of samples from the 29 ADCs. NCRAD also widely distributes samples both to investigators for their own analyses as well as to central cores, where APOE genotyping, genome wide SNP arrays, and now whole genome and whole exome sequencing studies are performed. We propose to expand our successful efforts with the following specific aims; 1. To provide a state-of-the-art central bio specimen repository for all NIA-funded dementia studies that includes detailed standard operating procedures for the secure banking of DNA, cell lines, plasma, serum, RNA, and brain tissue. 2. To facilitate and foster sample sharing by distributing data and biospecimens to all qualified investigators for use in their research studies. PUBLIC HEALTH RELEVANCE: There are a number of barriers that hamper the ability of researchers to perform successful studies of Alzheimer disease and related dementias. These include the ability to share samples, access to large numbers of high quality samples and effective sharing of research results. NCRAD under the advisement of NIA and CBAC will lift these ban-iers and facilitate sample and data sharing among dementia researchers.